Clinical Trial Update: LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating KB2115 as an add-on to ezetimibe in hypercholesterolemia has completed, assessing its LDL-cholesterol lowering effect.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• EZETIMIBE (EZETIMIBE)
• KB2115

Snippet

Sponsor: Karo Bio AB | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED